The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.Subscribe today
We won’t use CRISPR to make super-smart babies—but only because we can’t
Gene experts speculate that our worst gene-editing fears won’t come true because they are too complex for us to pull them off.
Electric nanoparticles can target and kill cancer cells by zapping them
Particles that produce electrical signals when bombarded with ultrasound could be a way to direct a cell-killing treatment directly to tumors.
Gene engineers make super-size plants that are 40% larger
Researchers hope to create a new “green revolution” by improving photosynthesis.